Hua Medicine, the leading innovative drug development and commercialization company in China, and Roche announced today a licensing agreement for Roche's Glucokinase Activator (GKA) program.
Hua Medicine, the leading innovative drug development and commercialization company in China, announced today that it has secured $50 million in new financing commitments from a prestigious group of US and Chinese healthcare investors, including ARCH Venture Partners, Fidelity Biosciences, Fidelity Growth Partners Asia, Venrock, Sino-Alliance International Ltd and new investor WuXi PharmaTech Corporate Venture.
Dear Hua Medicine Board Directors, Advisors, Colleagues, Partners and Friends